{"log_id": 6988515028458950525, "direction": 0, "words_result_num": 43, "words_result": [{"probability": {"variance": 0.021468, "average": 0.926589, "min": 0.397676}, "location": {"width": 787, "top": 184, "height": 26, "left": 207}, "words": "肠外途径给予亚叶酸:同时进行水化(31d)并用碳酸钠碱化尿液。调整碳酸氢钠的剂量"}, {"probability": {"variance": 0.018145, "average": 0.938792, "min": 0.498822}, "location": {"width": 785, "top": 217, "height": 27, "left": 209}, "words": "使尿PH值大于等于7。应该问24小时分析血清样本中肌西租甲氨蝶呤的水平。如果24"}, {"probability": {"variance": 0.011454, "average": 0.961304, "min": 0.459877}, "location": {"width": 785, "top": 248, "height": 26, "left": 209}, "words": "小时血清肌酐水平在基线上增长了50%或者如果24小时1氨蝶水平大于5x10M或48"}, {"probability": {"variance": 0.025664, "average": 0.910797, "min": 0.370968}, "location": {"width": 787, "top": 280, "height": 26, "left": 208}, "words": "小时甲氨蝶呤水平大于9x10M,那么亚叶酸钙的剂量应增加到100mg/m2每3小"}, {"probability": {"variance": 0.01086, "average": 0.955368, "min": 0.40003}, "location": {"width": 790, "top": 312, "height": 25, "left": 207}, "words": "时静脉注射直到甲氨蝶呤水平<10M。亚叶酸钙输注的速度不能超过每分钟16.0mL(160"}, {"probability": {"variance": 0.012897, "average": 0.950844, "min": 0.471138}, "location": {"width": 788, "top": 344, "height": 26, "left": 209}, "words": "0g亚叶酸钙)。有明显第3间隙蓄积的患者具有高风险,不论他们24小时血清甲氨蝶吟水"}, {"probability": {"variance": 0.011692, "average": 0.956165, "min": 0.529045}, "location": {"width": 479, "top": 374, "height": 25, "left": 208}, "words": "平如何都要持续监测直到血清甲氨蝶水平小于10M"}, {"probability": {"variance": 0.013798, "average": 0.940811, "min": 0.55295}, "location": {"width": 742, "top": 405, "height": 25, "left": 255}, "words": "以上所提到的业叶酸钙的剂量并不适期于大剂量甲氨蝶呤治疗中。在不同的研究和发"}, {"probability": {"variance": 0.027115, "average": 0.918523, "min": 0.360236}, "location": {"width": 758, "top": 436, "height": 24, "left": 209}, "words": "表的文献中亚叶液钙的剂有所不同,建议参发表的有大削量甲氨媒岭用药的文献"}, {"probability": {"variance": 0.015006, "average": 0.939526, "min": 0.497129}, "location": {"width": 743, "top": 465, "height": 26, "left": 254}, "words": "无论是标准的血液透析或者酸膜透析都不能明显改善事氨蝶岭的清除。如果患者完全"}, {"probability": {"variance": 0.011563, "average": 0.96542, "min": 0.474016}, "location": {"width": 778, "top": 497, "height": 26, "left": 210}, "words": "无尿,那么通过血液透析可能会清除部分甲氨蝶呤,此外也没有其它可以选择的治疗手段"}, {"probability": {"variance": 0.008082, "average": 0.960848, "min": 0.685997}, "location": {"width": 673, "top": 528, "height": 24, "left": 211}, "words": "有报道使用高通量透析器进行急性间断性血液透析对甲氨蝶呤的滑除是有效的"}, {"probability": {"variance": 4e-05, "average": 0.996051, "min": 0.98209}, "location": {"width": 112, "top": 588, "height": 25, "left": 217}, "words": "【药理毒理】"}, {"probability": {"variance": 0, "average": 0.998081, "min": 0.997844}, "location": {"width": 46, "top": 620, "height": 23, "left": 210}, "words": "药理"}, {"probability": {"variance": 0.028336, "average": 0.914687, "min": 0.353559}, "location": {"width": 747, "top": 652, "height": 26, "left": 251}, "words": "甲氨蝶呤的主要作用机理是争性邦制叶酸还原酶在DNA合成和细胞复制的过程中叶"}, {"probability": {"variance": 0.008705, "average": 0.954734, "min": 0.513977}, "location": {"width": 786, "top": 683, "height": 25, "left": 211}, "words": "酸必须被此酶还原成四氢叶酸。甲氨蝶呤抑制叶酸的还原,干扰了组织细胞的复制。甲"}, {"probability": {"variance": 0.005537, "average": 0.966407, "min": 0.587947}, "location": {"width": 784, "top": 716, "height": 24, "left": 212}, "words": "氨蝶呤是一种细胞周期特异性药物,它主要作用于DNA合成期的细胞。增殖活跃的组织如恶"}, {"probability": {"variance": 0.001874, "average": 0.983668, "min": 0.756165}, "location": {"width": 784, "top": 745, "height": 25, "left": 211}, "words": "性肿瘤细胞、骨髓、胚胎细胞、皮肤上皮细胞、口腔和肠粘膜以及膀胱细胞通常对甲氨蝶岭"}, {"probability": {"variance": 0.008041, "average": 0.963345, "min": 0.554271}, "location": {"width": 786, "top": 777, "height": 25, "left": 212}, "words": "作用更敏感恶性肿瘤组织中的细胞增殖比大部分正常组织中的更快,因此甲氨蝶呤可以削"}, {"probability": {"variance": 0.023226, "average": 0.942095, "min": 0.422521}, "location": {"width": 482, "top": 807, "height": 26, "left": 212}, "words": "弱恶性肿瘤的生长而不对正常织产生非可逆性的损伤"}, {"probability": {"variance": 0.020044, "average": 0.94845, "min": 0.36674}, "location": {"width": 748, "top": 837, "height": 27, "left": 251}, "words": "银屑病时皮肤上皮细胞的增能力远强干正常皮肤增殖率的差别正是使用甲氨蝶来"}, {"probability": {"variance": 0.000141, "average": 0.992884, "min": 0.966814}, "location": {"width": 205, "top": 870, "height": 24, "left": 211}, "words": "控制银屑病进展的基础"}, {"probability": {"variance": 0, "average": 0.998343, "min": 0.997813}, "location": {"width": 45, "top": 902, "height": 22, "left": 212}, "words": "毒理"}, {"probability": {"variance": 0.017946, "average": 0.933864, "min": 0.388988}, "location": {"width": 747, "top": 929, "height": 28, "left": 254}, "words": "体外,甲氨蝶呤引起中国仓鼠A(T1)C1-3细胞的染色体嘴变,诱导小鼠C3H/0T1/2克"}, {"probability": {"variance": 0.01025, "average": 0.966258, "min": 0.432633}, "location": {"width": 787, "top": 962, "height": 25, "left": 212}, "words": "隆8细胞的形态改变以及与小鼠淋巴瘤细胞L5178Y/k±的k基因突变率的增加有关。在体"}, {"probability": {"variance": 0.013355, "average": 0.96, "min": 0.417706}, "location": {"width": 786, "top": 992, "height": 26, "left": 213}, "words": "内,它引起小鼠体内多染性红细胞比率增加以及人类骨髓胞中染色体畸变数暂时的、可逆"}, {"probability": {"variance": 0.004047, "average": 0.963007, "min": 0.789039}, "location": {"width": 364, "top": 1024, "height": 26, "left": 213}, "words": "性的升高。这些发现的临床意义尚未明确"}, {"probability": {"variance": 4e-06, "average": 0.997596, "min": 0.992789}, "location": {"width": 165, "top": 1054, "height": 26, "left": 212}, "words": "致癌性和致突变性"}, {"probability": {"variance": 0.014367, "average": 0.939538, "min": 0.431021}, "location": {"width": 746, "top": 1086, "height": 26, "left": 253}, "words": "没有关十甲氨蝶致瘤风险的人类数据。些评估甲氨蝶呤潜在致癌性的动物研究目前"}, {"probability": {"variance": 1e-06, "average": 0.998066, "min": 0.996452}, "location": {"width": 147, "top": 1118, "height": 24, "left": 213}, "words": "尚无确定性结果"}, {"probability": {"variance": 0.005481, "average": 0.959741, "min": 0.679926}, "location": {"width": 579, "top": 1148, "height": 26, "left": 254}, "words": "有证据显示甲氨蝶呤引起动物体细胞和人类骨髓细胞的染色体损害"}, {"probability": {"variance": 0.005148, "average": 0.96702, "min": 0.65651}, "location": {"width": 746, "top": 1180, "height": 26, "left": 253}, "words": "在甲氨蝶呤单独或与其他药物联合使用前,尤是用于儿童雅青年人,应该分析获益与"}, {"probability": {"variance": 0.028008, "average": 0.874041, "min": 0.481136}, "location": {"width": 787, "top": 1209, "height": 30, "left": 213}, "words": "潜在风险。氨蝶岭会引起人类胚怡毒性、流产和胎儿畸形。山有报道在用药期间和停药后"}, {"probability": {"variance": 0.004573, "average": 0.969102, "min": 0.730015}, "location": {"width": 602, "top": 1241, "height": 32, "left": 214}, "words": "短时间内甲氨蝶呤会引起人类生育能力的损价、少精液症和经火调"}, {"probability": {"variance": 8e-06, "average": 0.998301, "min": 0.991904}, "location": {"width": 129, "top": 1306, "height": 24, "left": 222}, "words": "【药代动力学】"}, {"probability": {"variance": 0.003376, "average": 0.977308, "min": 0.64892}, "location": {"width": 736, "top": 1333, "height": 28, "left": 264}, "words": "吸收:在胃肠外注射后约0.5-2.0小时内观察到血浆峰浓度。约50%吸收的甲氨蝶"}, {"probability": {"variance": 0.01256, "average": 0.943352, "min": 0.582608}, "location": {"width": 701, "top": 1367, "height": 26, "left": 215}, "words": "呤可逆的与血清蛋白结合,但是仍然容易与体液进行交换并分布到人体组织细胞"}, {"probability": {"variance": 0.022971, "average": 0.925277, "min": 0.45043}, "location": {"width": 733, "top": 1398, "height": 26, "left": 269}, "words": "分布:甲氨蝶呤广泛分布于体内各组织,也可分布如水或胸腔积液之类的第三间隙"}, {"probability": {"variance": 0.02023, "average": 0.924311, "min": 0.350056}, "location": {"width": 785, "top": 1429, "height": 26, "left": 214}, "words": "积蓄的体液中。甲氨蝶呤装些组织中可滞留较长时间,如在肾脏可滞留数周,在肝脏中可"}, {"probability": {"variance": 0.020528, "average": 0.944124, "min": 0.360527}, "location": {"width": 781, "top": 1461, "height": 26, "left": 215}, "words": "滞留数月。当口服肠道外给予治疗剂量的甲氨蝶呤时,它不能通过血脑障。有必要时可"}, {"probability": {"variance": 0.014336, "average": 0.955724, "min": 0.513206}, "location": {"width": 307, "top": 1494, "height": 24, "left": 215}, "words": "以鞘内注射直接给予高浓度的药物"}, {"probability": {"variance": 0.015364, "average": 0.932317, "min": 0.526587}, "location": {"width": 731, "top": 1523, "height": 26, "left": 269}, "words": "代谢和排泄:當规剂量下,甲氨蝶呤在体内无明显代谢,而大剂量时,则可有部分代"}, {"probability": {"variance": 0.012033, "average": 0.947693, "min": 0.562125}, "location": {"width": 784, "top": 1556, "height": 26, "left": 217}, "words": "谢。清除符合三相模式,第一相可能是分布入器官中:第二相为肾脏排泄,第三相是将甲氨"}], "language": 3}